MET and non-small cell lung carcinoma: It has been established that MET plays a crucial role in mediating resistance to monotherapy with immune checkpoint inhibitors (ICIs), and the combination of MET inhibitors with anti-PD-L1 therapies may exhibit heightened efficacy in the treatment of NSCLC.